NewVale Capital Leads $20M Series C in Aizon
May 21, 2024
NewVale Capital led a $20 million Series C financing in Aizon to expand availability of its AI-powered software for GxP pharmaceutical manufacturing. The growth capital will support product development, scaling and commercial expansion to improve manufacturing outcomes for biopharma customers.
- Buyers
- NewVale Capital
- Targets
- Aizon
- Industry
- AI & Machine Learning
- Location
- California, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Bain Capital Tech Opportunities Invests R$450M in Bionexo
October 15, 2021
Cloud & SaaS
Bain Capital Tech Opportunities has made a R$450 million growth investment in Bionexo, a São Paulo–headquartered healthcare cloud software and data analytics provider. The funding will be used to expand Bionexo's suite of healthcare SaaS products, accelerate AI/ML development, and pursue transformational M&A to deepen its marketplace and supply‑chain capabilities across Latin America.
-
Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience
September 17, 2024
Pharmaceuticals
Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.
-
Vitruvian Partners and Lead Edge Capital Make Majority Growth Investment in Azul Systems
March 4, 2020
Software
London-based Vitruvian Partners, together with New York-based Lead Edge Capital, has agreed to make a majority growth equity investment in Sunnyvale-based Azul Systems. Azul's existing management will remain in place, shareholders are expected to receive approximately $340 million in consideration, and the investment will support product development, team scaling and potential strategic acquisitions to accelerate growth.
-
Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen
November 2, 2023
Biotechnology
Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.
-
Bain Capital Tech Opportunities Invests $150M in Axtria
May 13, 2021
Cloud & SaaS
Axtria, a Berkley Heights–based provider of cloud software and data analytics for the life sciences industry, received a $150 million growth investment from Bain Capital Tech Opportunities. The capital will be used to accelerate Axtria's expansion of its life-sciences-focused SaaS platforms, embed AI/ML capabilities across products, and support organic growth and M&A initiatives.
-
Accelmed Partners II and Lauxera Capital Invest in Veranex
November 14, 2022
Healthcare Services
Veranex has received strategic growth investments from Accelmed Partners II and Lauxera Capital Partners, joining existing investor Summit Partners, which retains majority ownership. The investments — terms undisclosed — will support Veranex’s continued global expansion and development of its integrated, tech‑enabled medical technology product development services; Uri Geiger (Accelmed) and Samuel Levy (Lauxera) joined Veranex’s board.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.